Scala Biodesign, a company developing algorithms to engineer proteins for medicine, food, and green production, today announced it has raised $5.5 million in seed funding. The round was led by TLV Partners, with participation from Intel Capital and angel investors.
Scala’s technology uses a combination of physics-based modeling, AI, and biological data analysis to design more active, stable, and cost-effective proteins than natural proteins. This makes it possible to develop new medicines, green production processes, and foods much faster and cheaper than traditional methods.
For example, Scala’s technology was used to improve a malaria vaccine that is now in Phase II clinical trials in West Africa. The technology has also been used to generate wood-degrading enzymes for biofuel production.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Dr. Ravit Netzer, CEO and Dr. Adi Goldenzweig, CTO, both are experts in protein engineering, founded the startup. They developed the company’s technology while conducting research at the Weizmann Institute of Science.
“We believe that Scala’s technology has the potential to revolutionize the field of protein engineering,” said Dr. Ravit Netzer, CEO of Scala Biodesign. “We are excited to use this funding to accelerate our development and commercialization efforts.”
Scala is currently working with a small group of early customers, including top-tier pharmaceutical companies. The company plans to use the new funding to expand its customer base and further develop its technology.
“We are very excited to partner with Scala Biodesign,” said Shahar Tzafrir, Managing Partner at TLV Partners. “The company’s technology has the potential to solve some of the most challenging problems in biology and medicine.”
Scala Biodesign is a graduate of the Intel Ignite acceleration program. The company is headquartered in Tel Aviv, Israel.
